Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1338042/000119312515293352/d943604d10q.htm
SEC Filings
AEGR Annual Reports
AEGR Quarterly Reports
AEGR Corporate News
Bylaw Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
New Agreement
Security Holders Change November 2016
Vote of Security Holders November 2016
Earnings Release November 2016
Other Events October 2016
Other Events October 2016
Financial Exhibit
Other Events October 2016
Earnings Release
Financial Exhibit August 2016
Financial Exhibit
Other Events August 2016
Event for Officers
Financial Exhibit
New Agreement
New Costs July 2016
Vote of Security Holders July 2016
Bylaw Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
New Agreement
Security Holders Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
New Agreement
Security Holders Change
November 2016
Vote of Security Holders
November 2016
Earnings Release
November 2016
Other Events
October 2016
Other Events
October 2016
Financial Exhibit
Other Events
Other Events
October 2016
Earnings Release
Financial Exhibit
Financial Exhibit
August 2016
Financial Exhibit
Other Events
Other Events
August 2016
Event for Officers
Financial Exhibit
New Agreement
New Costs
Financial Exhibit
New Agreement
New Costs
July 2016
Vote of Security Holders
July 2016
Last10K.com | 10-Q Quarterly Report Mon Aug 17 2015
Exhibit 99.1
AEGERION PHARMACEUTICALS ANNOUNCES
SECOND QUARTER 2015 FINANCIAL RESULTS
- Company records $64.2 million in total net product sales -
- JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. -
- Company reiterates 2015 total net product sales guidance of between $205 and $235 million -
Cambridge, MA, August 5, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the second quarter of 2015.
Highlights
| • | Aegerion recorded $57.1 million in net product sales of JUXTAPID® (lomitapide) capsules in the second quarter of 2015, representing growth of approximately 59% over the second quarter of 2014. 96% of JUXTAPID net product sales in the second quarter of 2015 were from prescriptions written in the United States. |
| • | Aegerion recorded $7.1 million in net product sales of MYALEPT® (metreleptin for injection) in the second quarter of 2015, all of which were from prescriptions written in the United States. As of July 31, 2015, 68 generalized lipodystrophy (GL) patients were active on commercial therapy. |
| • | Aegerion’s cash increased by $15.2 million in the second quarter of 2015. |
| • | The Company is on track with its plan to file a Japanese NDA for lomitapide in adult HoFH patients late 2015 or early 2016. The Company anticipates a nine month review period as a result of lomitapide’s orphan drug status. |
Chief Executive Officer Sandford D. Smith commented, “Aegerion continued to show good progress during the second quarter in key areas of the business, including growth in number of patients on therapy for both of our products. We believe we are on track to deliver strong results; however, as we navigate through the early days of the PCSK9 inhibitor launches, we are maintaining our prior guidance for the year. We remain focused on building a fully integrated, leverageable and risk-diversified company to deliver therapies to patients with rare diseases.”
“With the objective of maximizing the value of our current assets, we have focused attention and resources on expanding the opportunities for both MYALEPT and JUXTAPID by prioritizing investments in research and development to support the
The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Wednesday, August 5, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aegerion Pharmaceuticals, Inc..
Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Loss
Condensed Consolidated Statements Of Operations
Accrued Liabilities
Accrued Liabilities (tables)
Accrued Liabilities - Components Of Accrued Liabilities (detail)
Basic And Diluted Net Loss Per Common Share
Basic And Diluted Net Loss Per Common Share (tables)
Basic And Diluted Net Loss Per Common Share - Anti-dilutive Securities Excluded From Computation (detail)
Business Acquisitions
Business Acquisitions (tables)
Business Acquisitions - Additional Information (detail)
Business Acquisitions - Pro Forma Impact Of Acquisition (detail)
Business Acquisitions - Summary Of Estimated Fair Values Of Net Assets Acquired (detail)
Business Acquisitions - Summary Of Preliminary Fair Values Assigned To Assets Acquired And Amortization Period Assigned (detail)
Capital Structure
Capital Structure - Additional Information (detail)
Commitments And Contingencies
Debt Financing
Debt Financing (tables)
Debt Financing - Additional Information (detail)
Debt Financing - Schedule Of Outstanding Convertible Note Balances (detail)
Debt Financing - Schedule Of Total Interest Expense Recognized Related To Convertible Notes (detail)
Debt Financing - Summary Of Future Minimum Payments Under Convertible Notes (detail)
Debt Financing - Summary Of Future Minimum Payments Under Term Loan Agreements (detail)
Description Of Business And Significant Accounting Policies
Description Of Business And Significant Accounting Policies (policies)
Description Of Business And Significant Accounting Policies - Additional Information (detail)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (tables)
Fair Value Of Financial Instruments - Additional Information (detail)
Fair Value Of Financial Instruments - Fair Value Measurements Of Financial Instruments (detail)
Income Taxes
Income Taxes - Additional Information (detail)
Inventories
Inventories (tables)
Inventories - Components Of Inventory (detail)
Other Comprehensive Loss And Accumulated Other Comprehensive Items
Other Comprehensive Loss And Accumulated Other Comprehensive Items (tables)
Other Comprehensive Loss And Accumulated Other Comprehensive Items - Additional Information (detail)
Other Comprehensive Loss And Accumulated Other Comprehensive Items - Summary Of Other Comprehensive Loss And Changes In Accumulated Other Comprehensive Items (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Allocation Of Stock-based Compensation Expense By Type Of Award (detail)
Stock-based Compensation - Allocation Of Stock-based Compensation Expense To Statements Of Operations (detail)
Stock-based Compensation - Summary Of Restricted Stock Units Activity (detail)
Stock-based Compensation - Summary Of Stock Option Activity (detail)
Stock-based Compensation - Weighted-average Assumptions To Estimate Fair Value (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Material Contracts, Statements, Certifications & more
Aegerion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: AEGR
CIK: 1338042
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-15-293352
Submitted to the SEC: Mon Aug 17 2015 5:09:15 PM EST
Accepted by the SEC: Mon Aug 17 2015
Period: Tuesday, June 30, 2015
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/aegr/0001193125-15-293352.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...